Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance Phase 1b/2 NMIBC Trial on Track: Initial 3-Month Clinical Data Expected Mid-2026 ...
Barchart Research What to Expect from AURA Earnings AURA Generated March 27, 2026 Current Price $6.27 EPS Estimate $-0.43 Consensus Rating Strong Buy Average Move 3.65% Aura Biosciences Has Been Quietly...
Barchart Research What to Expect from AURA Earnings AURA Generated March 27, 2026 Current Price $6.27 EPS Estimate $-0.43 Consensus Rating Strong Buy Average Move 3.65% Aura Biosciences Has Been Quietly...
Barchart Research What to Expect from AURA Earnings AURA Generated March 27, 2026 Current Price $6.27 EPS Estimate $-0.43 Consensus Rating Strong Buy Average Move 3.65% Aura Biosciences Has Been Quietly...
BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. Â (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function,...
BOSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ...
Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 Program The...
Aura Provides Phase 3 CoMpass Trial Completion Guidance: 2026 Enrollment Completion and Q4 2027 Topline Data Readout for the 15-Month Primary Endpoint Immune Profiling Data Reveal Bel-sar’s Potential...
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. Â (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ...
Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC) Strengthened Balance Sheet with...